Abbisko Therapeutics will present updated Phase 2 results of irpagratinib combined with atezolizumab for advanced hepatocellular carcinoma at the 2025 ESMO GI Congress in Barcelona.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.